Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of three doses of nasal GLP-1 versus placebo on postprandial hyperglycaemia in type 2 diabetes
2005-003760-38Phase 2Completed
- Sponsor
- Sten Madsbad
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of Glucagon-like peptide 1 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sten Madsbad. Primary endpoints: Changes in glucose control and Changes in GLP-1 concentrations. Started Sep 2005; status: completed.
02
Drugs
Glucagon-like peptide 1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-003760-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003760-38.